AstraZeneca: Tagrisso plus savolitinib extends median overall survival by nearly five months in EGFRm lung cancer

AstraZeneca announced at ESMO on Sunday that Tagrisso plus savolitinib extended median overall survival by nearly five months in patients with EGFR-mutated lung cancer.

Detected & updated continuously · Source: Nebula